|
|
(HealthNewsDigest.com) – ATLANTA – Researchers at Emory University School of Medicine, New York-Presbyterian/Weill Cornell Medical Center and the University of Southern California have been awarded an $11 million Department of Defense grant to test two different types of exposure therapy combined with the drug D-Cycloserine (DCS) for the treatment of Posttraumatic Stress Disorder (PTSD).
Exposure therapy is an evidence-based intervention that has been demonstrated as effective in the treatment of PTSD. During each exposure therapy session, patients repeatedly retell their traumatic experience with the guidance of a trained clinician. D-Cycloserine, a cognitive enhancer, has been found by Emory researchers to facilitate the extinction of fear that occurs during exposure therapy.
The study will involve military and civilian personnel who have been diagnosed with PTSD as a consequence of their service in the Iraq and Afghanistan wars. The goal of the trial is to decrease the time of effective treatment for PTSD, give the right treatment to the right person and identify factors involved in its development and response to treatment.
The researchers also will examine personal and genetic factors that may impact an individual’s chances of developing PTSD.
Full Release: http://bit.ly/RothbaumDOD_PTSD_2011
Check us out via social media: http://bit.ly/emoryhealthscisocial
####
For advertising and promotion on HealthNewsDigest.com please contact Mike McCurdy: [email protected] or 877-634-9180
HealthNewsDigest.com is syndicated worldwide and has over 7,000 journalists as subscribers.